Therapeutic targeting of refractory/relapsed diffuse large B-cell lymphoma through systems biology

In Diffuse Large B-cell Lymphoma (DLBCL), elevated anti-apoptotic BCL2-family proteins (e.g., MCL1, BCL2, BCLXL) and NF-κB subunits …

Decades of research into the molecular signalling determinants of B cell fates, and recent progress in characterising the genetic …

Combining mathematical modeling with experiments enables quantitative understanding of cell signaling, transcriptional regulation, and …

Genetic heterogeneity and co-occurring driver mutations impact clinical outcomes in blood cancers, but predicting the emergent effect …

In healthy cells, pro- and anti-apoptotic BCL2 family and BH3-only proteins are expressed in a delicate equilibrium. In contrast, this …

Introduction. Improving treatments for Diffuse Large B-Cell Lymphoma (DLBCL) is challenged by the vast heterogeneity of the disease. …

Chronic lymphocytic leukemia (CLL) is the most prevalent type of leukemia in the western world. Despite the positive clinical effects …

The nuclear factor κB (NF-κB) system is critical for various biological functions in numerous cell types, including the inflammatory …

The paper combines in vitro, in vivo, and in silico systems biology to understand how BH3-mimetic sensitivity is controlled in the …

Dr Mitchell recently presented in New York at the Cold Spring Harbor Laboratory - Systems Immunology conference. Watch the talk here.

A new pre-print led by Aimilia asks why drugs that kill cancer cells in blood don’t kill them in lymph nodes? How we can fix …

Richard has received a funding award to travel to EMBO Computational Models of Life 2023 and to share his latest findings in Spain.

Simon Mitchell received the Emerging Impact Award (any career stage), recognising the team’s efforts lay the foundation for personalised medicine in blood cancer using systems biology. Announced during Sussex Research Impact Awards 2023, the award is designed to recognise efforts to prepare and progress the fundamentals important for developing impact.

The Sussex ECR Dragons’ Den was a competative mutli-round process that saw talented early career reseachers from across the University of Sussex make their pitch for why they should receive research funding to kick start their impactful ideas.

Leukaemia UK have written an article entitled: “Leukaemia UK research paves the way for personalised lymphoma treatment” highlighting our recent publication successes. Read the full article here.

Two papers published within 4 days of each other. One in Frontiers in Oncology, lead by Eleanor Jayawant and in NPJ Systems Biology and Applications lead by Ielyaas Cloete. Check out the links above to each paper, or see all of our publications here.

In “The NF-κB multidimer system model: A knowledge base to explore diverse biological contexts” we answer how a highly conserved system can do very different things in different contexts. Congratulations to Arran for his first publiction in the Mitchell lab, as this paper includes a part of his PhD thesis.

Dr Mitchell will deliver a seminar on using systems biology approaches to understanding B cell fate decisions in health and lymphoma.

Dr Mitchell recently gave a BSMS outreach lecture, where he answered: What is systems biology? How can we simulate life? How does that help us treat cancer ? What might the future of cancer treatment look like?

We have had two projects accepted for talks and two projects accepted for posters at the 21st International Conference on Systems Biology.

LyMIT 2022 attracts international speakers and audience.

We are hosting a new meeting we are hosting on research into Lymphoid Malignancies with Interdisciplinary Techniques (LyMIT), which will take place on the 6th September 2022.

We are excited to share that the Mitchell Lab have had two abstracts accepted for the European Haematology Associations annual congress, EHA2022, June 9th-12th 2022.

The Mitchell group are participating the European School of Haematology’s 6th Translational Research Conference on Lymphoid Malignancies (ESH Lymphoid 2021) (Oct 14-17 2021). A number of our members presenting research updates, which are available to view now!

The entire Mitchell group will be participating in SMB 2021 (June 13-17, 2021) with a number of members presenting research updates. Ielyaas Cloete will present his progress in simulating apoptotic signaling networks to enable better understanding their role in B-Cell lymphoma.

Simon has been invited to present at the European Haematology Associations annual congress, June 9th-17th 2021. Simon will present his progress in understanding diffuse large B-cell lymphoma through systems biology. His presentation “A SYSTEMS BIOLOGY APPROACH TO DLBCL PREDICTS EMERGENT PHENOTYPES FROM MOLECULAR DYSREGULATION AND IDENTIFIES DISTINCT ROLES FOR NF-KB SUBUNITS CREL AND RELA.

Dr Mitchell was recently awarded a prestigious £1.2m UKRI Future Leaders Fellowship to tackle Relapsed/Refractory DLBCL with Systems Biology approaches. The UKRI Future Leaders scheme invests in early career researchers and innovators with outstanding potential, helping them to develop their careers while tackling ambitious challenges.